Targeting Neuroimmune Interactions in Diabetic Neuropathy with Nanomedicine

Mihaly Balogh, Jelena M. Janjic*, Andrew J. Shepherd*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

34 Downloads (Pure)


Significance: Diabetes is a major source of neuropathy and neuropathic pain that is set to continue growing in prevalence. Diabetic peripheral neuropathy (DPN) and pain associated with diabetes are not adequately managed by current treatment regimens. Perhaps the greatest difficulty in treating DPN is the complex pathophysiology, which involves aspects of metabolic disruption and neurotrophic deficits, along with neuroimmune interactions. There is, therefore, an urgent need to pursue novel therapeutic options targeting the key cellular and molecular players.

Recent Advances: To that end, cellular targeting becomes an increasingly compelling drug delivery option as our knowledge of neuroimmune interactions continues to mount. These nanomedicine-based approaches afford a potentially unparalleled specificity and longevity of drug targeting, using novel or established compounds, all while minimizing off-target effects.

Critical Issues: The DPN therapeutics directly targeted at the nervous system make up the bulk of currently available treatment options. However, there are significant opportunities based on the targeting of non-neuronal cells and neuroimmune interactions in DPN.
Original languageEnglish
Pages (from-to)122-143
JournalAntioxidants & Redox Signaling
Issue number1-3
Early online date20-Aug-2021
Publication statusPublished - 17-Jan-2022
Externally publishedYes

Cite this